Skip to content

Air Optix® Night and Day® Aqua Daily Wear

Air Optix® Night and Day® Aqua Daily Wear

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05976750
Enrollment
102
Registered
2023-08-04
Start date
2023-10-03
Completion date
2024-07-30
Last updated
2024-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractive Errors, Myopia, Hyperopia

Brief summary

The purpose of this Post-Market Clinical Follow-Up (PMCF) study is to assess long term performance and safety of Air Optix® Night and Day® Aqua (AONDA) contact lenses in a real-world setting when worn as daily wear for vision correction.

Detailed description

This is a non-interventional/observational study designed as a retrospective chart review. Study sites will review charts within their existing database to identify subjects who wore AONDA contact lenses or PureVision® 2 (PV2) contact lenses in both eyes for approximately 1 year following their contact lens examination. The data collection period consists of any approximately 1-year timeframe since and including 2009. The anticipated duration of the study is approximately 6 months.

Interventions

CE-marked silicone hydrogel contact lenses for daily wear use

CE-marked silicone hydrogel contact lenses for daily wear use

Sponsors

Alcon Research
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Normal eyes, as determined by the Investigator * At the time of the 1-year visit, subject was prescribed and wearing AONDA contact lenses or PV2 contact lenses in both eyes in a daily wear modality for at least approximately 1 year without changing wear modality * Baseline and 1-year visit charts available * Other protocol-specified inclusion criteria may apply

Exclusion criteria

* Any recurrent history or active anterior segment infection, inflammation, abnormality, or disease contraindicating regular contact lens wear present at Baseline * Use of systemic or ocular medications contraindicating regular contact lens wear at Baseline * History of refractive surgery or irregular cornea * Other protocol-specified

Design outcomes

Primary

MeasureTime frameDescription
Distance visual acuity by eyeYear 1The subject's chart will be reviewed for distance visual acuity.
Incidence of corneal infiltrative eventsUp to Year 1The subject's chart will be reviewed for incidences of corneal infiltrative events occurring after the baseline exam.
Incidence of microbial keratitisUp to Year 1The subject's chart will be reviewed for incidences of microbial keratitis occurring after the baseline exam.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026